Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jing Tong Ke Li is a Traditional Chinese Medicine (TCM) granule primarily indicated for the treatment of cervical spondylosis, specifically the nerve root type (cervical radiculopathy). Developed and manufactured by Shandong Buchang Pharmaceuticals, the formulation is a combination of several botanical extracts, including *Panax notoginseng*, *Astragalus membranaceus*, *Pueraria lobata*, and *Ligusticum chuanxiong*. Its therapeutic mechanism involves promoting blood circulation to remove stasis, tonifying Qi, and dredging meridians to alleviate pain and inflammation associated with cervical disc degeneration and nerve compression. It is widely used in China to treat symptoms such as neck pain, stiffness, and radiating numbness in the upper limbs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on jingtong granule.